You are here

Our science / Clinical Trials / Find a Trial / NCT01877239

Study to Observe the Safety and Efficacy of Etanercept (Enbrel®) in Patients With Moderately Active Rheumatoid Arthritis in Every Day Clinical Practice in Austria

Back to Search Print Save as PDF Bookmark Trial

NCT01877239

Last updated on October 20, 2019
Back to Search Print Save as PDF Bookmark Trial

FOR MORE INFORMATION
Study Location
Ordination Dr. Thomas Muller
Graz, , 8010 Austria
See other locations
Contact
1-800-718-1021
[email protected]
Related Links
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Rheumatoid Arthritis
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

1. The patient is eligible to receive Etanercept treatment according to the Austrian
SmPC.

2. The decision to treat the patient with Etanercept has been made independently by the
physician and is clearly separated from the decision to include the patient in the
study. The treatment decision was made in advance and is not dependent on the
protocol.

3. The patient was informed about the study and gave his/her consent and signed an
Independent Ethics Committee (IEC) submitted written Informed Consent form on use of
the data.

4. The patient has moderately active RA, defined as a disease activity of CDAI >10 and
≤22 and/or DAS28 (CRP)>3.2 and ≤ 5.1

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

1. Any contraindication according to the Austrian SmPC, which includes:

A hypersensitivity to any component of Etanercept, active tuberculosis or any other
serious infection.

2. Patient has previously participated in this study.

NCT01877239
Pfizer
Completed
Study to Observe the Safety and Efficacy of Etanercept (Enbrel®) in Patients With Moderately Active Rheumatoid Arthritis in Every Day Clinical Practice in Austria

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Advanced Search

Based on your search, you may also be interested in

Rheumatoid Arthritis
Infliximab Biosimilar for Intravenous Drip Infusion 100 mg "Pfizer" Drug Use Investigation (Rheumatoid Arthritis)
NCT03885037
All Genders
0+
Years
Tokyo,
Rheumatoid Arthritis
Rheumatoid Arthritis Satisfaction Outcome Research
NCT03703817
All Genders
19+
Years
Multiple Sites
Systemic Lupus Erythematosus, Rheumatoid Arthritis
Safety and Tolerability Study Of PF-06835375 In Subjects With Seropositive Systemic Lupus Erythematosus Or Rheumatoid Arthritis
NCT03334851
All Genders
18+
Years
Multiple Sites
Rheumatoid Arthritis
Observational Study to Determine How Physicians Make Treatment Decisions in Patients Treated With Tofacitinib for Moderate to Severe Active Rheumatoid Arthritis
NCT03387423
All Genders
18+
Years
Multiple Sites
Descriptive Information
Brief TitleStudy to Observe the Safety and Efficacy of Etanercept (Enbrel®) in Patients With Moderately Active Rheumatoid Arthritis in Every Day Clinical Practice in Austria
Official TitleA Multicenter Non-interventional Study To Observe The Safety And Efficacy Of Etanercept (Enbrel (Registered)) In Patients With Moderately Active Rheumatoid Arthritis In Every Day Clinical Practice In Austria
Brief SummaryThis is a prospective non-interventional observational study to evaluate the treatment of moderately active RA patients in every day clinical practice in Austria. Patients will be observed over 52 weeks. The primary endpoint will be percentage of patients who reach CDAI remission after 24 weeks.
Detailed DescriptionNon-interventional observational study, national, multicenter prospective non-interventional study (NIS) as defined by the Austrian Drug Law § 2a Section 3 N/A
Study TypeObservational
Study DesignObservational Model: Other
Time Perspective: Prospective
Target Follow-Up DurationNot Provided
BiospecimenNot Provided
Sampling MethodNon-Probability Sample
Study PopulationPatients with moderately active RA that are treated with Etanercept will be studied. All patients enrolled should meet the usual prescribing criteria for Etanercept as per the Austrian SmPC and should be entered into the study at the investigator's discretion.
ConditionRheumatoid Arthritis
InterventionOther: non-intervention
observation of Etanercept treatment in moderately active RA patients in Austria. Etanercept treatment according to Austrian SmPC
Study Groups/CohortsFull Analysis Set
Full Analysis Set (FAS): The FAS contains any patient that has given written informed consent.
Intervention: Other: non-intervention
Publications *Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment StatusCompleted
Actual Enrollment
 (submitted: April 30, 2018)		111
Original Estimated Enrollment
 (submitted: June 12, 2013)		120
Actual Study Completion DateJune 14, 2016
Actual Primary Completion DateJanuary 7, 2016   (Final data collection date for primary outcome measure)
Eligibility Criteria

Inclusion Criteria:

  1. The patient is eligible to receive Etanercept treatment according to the Austrian SmPC.
  2. The decision to treat the patient with Etanercept has been made independently by the physician and is clearly separated from the decision to include the patient in the study. The treatment decision was made in advance and is not dependent on the protocol.
  3. The patient was informed about the study and gave his/her consent and signed an Independent Ethics Committee (IEC) submitted written Informed Consent form on use of the data.
  4. The patient has moderately active RA, defined as a disease activity of CDAI >10 and ?22 and/or DAS28 (CRP)>3.2 and ? 5.1

Exclusion Criteria:

  1. Any contraindication according to the Austrian SmPC, which includes:

    A hypersensitivity to any component of Etanercept, active tuberculosis or any other serious infection.

  2. Patient has previously participated in this study.
Sex/Gender
Sexes Eligible for Study:All
Ages18 Years and older   (Adult, Older Adult)
Accepts Healthy VolunteersNo
ContactsContact information is only displayed when the study is recruiting subjects
Listed Location CountriesAustria
Removed Location Countries  
 
Administrative Information
NCT NumberNCT01877239
Other Study ID NumbersB1801357
Has Data Monitoring CommitteeNo
U.S. FDA-regulated ProductNot Provided
IPD Sharing StatementNot Provided
Responsible PartyPfizer
Study SponsorPfizer
CollaboratorsNot Provided
Investigators
Study Director:Pfizer CT.gov Call CenterPfizer
PRS AccountPfizer
Verification DateApril 2018

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now